IMNM Insider Update: CTO Receives 190,000 Stock Options

Q: What insider activity was reported for IMNM?

CTO Philip Tsai received options for 190,000 shares at a $10.60 strike price.

Q: When do the IMNM options granted to the CTO vest?

25 % vests on 29-Jul-2026 ; the rest vests monthly over the following 36 months.

Q: Did the CTO buy or sell any Immunome common shares?

No. The Form 4 shows only an option grant ; no shares were bought or sold.

Q: What is the expiration date of the new IMNM options?

The options expire on 28-Jul-2035 .

Q: How many derivative securities does the CTO own after this filing?

He beneficially owns 190,000 stock options following the reported transaction.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Immunome, Inc. (IMNM) – Form 4 insider filing

Chief Technical Officer Philip Tsai was granted an employee stock option for 190,000 common shares on 29-Jul-2025 at an exercise price of $10.60. The options expire on 28-Jul-2035. No common shares were bought, sold or otherwise transferred in the filing; the entire award is reported as directly owned.

Vesting schedule: 25 % of the grant vests on 29-Jul-2026; the remaining 75 % vests in 36 equal monthly installments thereafter. Following this grant, Tsai beneficially owns 190,000 derivative securities (options) and no change to his non-derivative share count is disclosed.

The transaction is a routine equity incentive meant to align executive interests with shareholders. Dilution will only occur if the options are exercised at prices above $10.60.

Positive

Executive-shareholder alignment: Option grant incentivises CTO performance over a 10-year horizon.

Negative

Potential dilution: 190,000 additional shares could enter the float if options are exercised.

Insights

TL;DR: Routine CTO option grant; neutral impact, aligns incentives, minor potential dilution.

The 190 k option award represents future, not immediate, ownership. With a 10-year term and a strike near recent trading levels, it is intended to motivate long-term value creation. No shares were sold, so the filing conveys no bearish insider signal. Dilution will be limited and contingent upon exercise; without the company’s current share count, the percentage can’t be quantified, but grants of this size are typically immaterial for small-mid biotech floats. Overall, the filing is informational rather than market-moving.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Tsai Philip

Role Chief Technical Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	190,000	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 190,000 shares (Direct)

Footnotes (1)

[object Object]

Form 4 Insider Transactions: What Each Field Means →

07/31/2025 - 07:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tsai Philip

(Last)

(First)

(Middle)

C/O IMMUNOME, INC.

18702 N. CREEK PARKWAY, SUITE 100

(Street)

BOTHELL

98011

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Immunome Inc. [ IMNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Technical Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Employee Stock Option (right to buy)	$10.6	07/29/2025		A		190,000		⁽¹⁾	07/28/2035	Common Stock	190,000	$0	190,000	D

Explanation of Responses:

1. 25% of the shares subject to the options vest on July 29, 2026, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter.

	/s/ Sandra Stoneman, Attorney-in-Fact	07/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity was reported for IMNM?

CTO Philip Tsai received options for 190,000 shares at a $10.60 strike price.

When do the IMNM options granted to the CTO vest?

25 % vests on 29-Jul-2026; the rest vests monthly over the following 36 months.

Did the CTO buy or sell any Immunome common shares?

No. The Form 4 shows only an option grant; no shares were bought or sold.

What is the expiration date of the new IMNM options?

The options expire on 28-Jul-2035.

How many derivative securities does the CTO own after this filing?

He beneficially owns 190,000 stock options following the reported transaction.